College of Pharmacy, Southwest Minzu University, Chengdu, Sichuan, P.R.China.
J Chemother. 2021 Nov;33(7):452-461. doi: 10.1080/1120009X.2021.1884797. Epub 2021 Feb 15.
Fatigue was a frequently reported adverse event associated with the use of PARP inhibitors. We performed a systematic review and meta-analysis to fully investigate the fatigue of PARP inhibitors in cancer patients. Databases were searched for randomized controlled trials (RCTs) treated with PARP inhibitors till July 2020. Twenty-nine RCTs and 9479 patients were included. This meta-analysis suggests that the use of PARP inhibitors significantly increase the risk of developing all-grade (RR, 1.25; 95%CI, 1.20-1.31; < 0.00001; I = 48%) and high-grade fatigue (RR, 1.92; 95%CI, 1.51-2.45; < 0.00001; I = 11%). Veliparib was associated with a relatively lower risk of fatigue. Patients with ovarian cancer tend to be associated with a higher risk of fatigue than those with non-ovarian cancer. Longer duration of therapy was associated with a higher risk of all-grade fatigue. Patients receiving PARP inhibitor monotherapy tends to be associated with a higher risk of all-grade fatigue than those receiving combination treatment.
疲劳是与 PARP 抑制剂使用相关的一种常见不良反应事件。我们进行了一项系统评价和荟萃分析，以全面研究 PARP 抑制剂在癌症患者中的疲劳情况。检索了截至 2020 年 7 月接受 PARP 抑制剂治疗的随机对照试验（RCT）的数据库。纳入了 29 项 RCT 和 9479 名患者。这项荟萃分析表明，PARP 抑制剂的使用显著增加了发生所有级别（RR，1.25；95%CI，1.20-1.31； < 0.00001；I = 48%）和高级别疲劳（RR，1.92；95%CI，1.51-2.45； < 0.00001；I = 11%）的风险。Veliparib 与疲劳风险相对较低相关。与非卵巢癌患者相比，卵巢癌患者更易发生疲劳。治疗持续时间较长与所有级别疲劳的风险增加相关。与接受联合治疗的患者相比，接受 PARP 抑制剂单药治疗的患者更易发生所有级别疲劳。
